✦ LIBER ✦

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial

✍ Scribed by Baptist Gallwitz; Juan Guzman; Francesco Dotta; Bruno Guerci; Rafael Simó; Bruce R Basson; Andreas Festa; Jacek Kiljański; Hélène Sapin; Michael Trautmann; Guntram Schernthaner

Book ID: 117310106
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 363 KB
Volume: 379
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(12)60479-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Liraglutide versus sitagliptin for patie

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

✍ Richard E Pratley; Michael Nauck; Timothy Bailey; Eduard Montanya; Robert Cuddih 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 345 KB

Improved glycaemic control of thrice-dai

Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes

✍ M. R. Clements; J. Tits; B. T. Kinsley; J. Råstam; H. H. Friberg; R. J. Ligthelm 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 241 KB

Comparison of biphasic insulin aspart 30

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: A 16-week, randomized, open-label, parallel-group trial conducted in russia

✍ Olga Ushakova; Vera Sokolovskaya; Alla Morozova; Farida Valeeva; Olga Zanozina; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 858 KB

One year of liraglutide treatment offers

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial

✍ R. Pratley; M. Nauck; T. Bailey; E. Montanya; R. Cuddihy; S. Filetti; A. Garber; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 510 KB